Abstract
Background
Patients with localized prostate cancer (PCa) experience biochemical recurrence (BCR) despite a curatively intended radical prostatectomy (RP). The aim of this study was to describe the quality of life (QoL) of patients with a BCR while identifying predictors of early (ER) and late recurrence (LR).
Methods
For this purpose, a total of 330 PCa patients with a BCR following RP at Charité University Hospital in Berlin were analyzed. BCR was defined as two consecutive PSA values ≥ 0.2 after a previous non-detectable level. LR was defined as a BCR after 3 years post-RP. Differences in overall survival (OS) were calculated using the log-rank testing. A logistic regression model was applied to identify predictors of ER and LR. We further evaluated difference between ER and LR with respect to functional outcomes in urinary and sexual domains as well as the patients QoL.
Results
Out of 330 patients, 180 patients showed late BCR. Patients rated their global QoL with 64.5% in ER and 68.8% LR as good (EORTC quality of life Questionnaire, question 29 and 30). The questionnaire did not reveal QoL differences in terms of sexual and urinary function within ER and LR. The main predictor for LR was preoperative serum prostate-specific antigen (PSA) levels with a relative risk (RR) of 0.96 (p = 0.011). OS for patients with LR was significant longer than for patients with ER (154.3 vs. 143.2 months, p = 0.018).
Conclusion
Patients with a BCR show a good quality of life possibly irrespective of the time point of BCR. We further identified preoperative PSA levels as a predictor of LR and noted that patients with LR patients lived longer. Further studies are needed.
Similar content being viewed by others
Abbreviations
- ADT:
-
Androgen deprivation therapy
- BCR:
-
Biochemical recurrence
- CSM:
-
Cancer-specific mortality
- ER:
-
Early recurrence
- LR:
-
Late recurrence
- LRP:
-
Laparoscopic radical prostatectomy
- OS:
-
Overall survival
- PCa:
-
Prostate cancer
- PCSM:
-
Prostate cancer-specific survival
- PLND:
-
Pelvic lymph node dissection
- PSA:
-
Prostate-specific antigen
- PSADT:
-
PSA doubling time
- PSM:
-
Positive surgical margin
- QoL:
-
Quality of life
- RP:
-
Radical prostatectomy
- RR:
-
Relative risk
- SRT:
-
Salvage radiation therapy
References
American Cancer Society. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html. Accessed June 2019
Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433–439
Tanaka N, Hirayama A, Yoneda T, Yoshida K, Shimada K, Konishi N, Fujimoto K (2013) Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)—a comparison between 2004–2006 and 2007–2009. BMC Cancer 13:588
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591–1597
D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH (2003) Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95:1376–1383
Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, Karnes RJ (2011) Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 59:893–899
Mottet N, van den Bergh RCN, Briers E, Bourke L, Cornford P, De Santis M, Gillessen S, Govorov A, Grummet J, Henry AM, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Van den Broeck T, Cumberbatch M, Fossati N, Gross T, Lardas M, Liew M, Moris L, Schoots IG, Willemse PM (2018) EAU-ESTRO-ESRU-SIOG guidelines on Prostate Cancer
Briganti A, Karnes RJ, Gandaglia G, Spahn M, Gontero P, Tosco L, Kneitz B, Chun FK, Zaffuto E, Sun M et al (2015) Natural history of surgically treated high-risk prostate cancer. Urol Oncol 33(163):e7–13
Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299:2760–2769
D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH (2004) Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172:S42–S46 (discussion S46–S47)
Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA (2012) The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 109:32–39
Brockman JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, Lin DW, Bianco FJ Jr, Rabah DM, Klein EA et al (2015) Nomogram predicting prostate cancer-specific mortality for men with biochemical recurrence after radical prostatectomy. Eur Urol 67:1160–1167
Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H (2001) Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 165:1146–1151
Toussi A, Stewart-Merrill SB, Boorjian SA, Psutka SP, Thompson RH, Frank I, Tollefson MK, Gettman MT, Carlson RE, Rangel LJ, Karnes RJ (2016) Standardizing the definition of biochemical recurrence after radical prostatectomy-what prostate specific antigen cut point best predicts a durable increase and subsequent systemic progression? J Urol 195:1754–1759
Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, Scardino PT (2006) Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24:3973–3978
Sowerby RJ, Gani J, Yim H, Radomski SB, Catton C (2014) Long-term complications in men who have early or late radiotherapy after radical prostatectomy. Can Urol Assoc J 8:253–258
Fontaine E, Ben Mouelli S, Thomas L, Otmezguine Y, Beurton D (2004) Urinary continence after salvage radiation therapy following radical prostatectomy, assessed by a self-administered questionnaire: a prospective study. BJU Int 94:521–523
Gonzalez BD, Jim HSL, Small BJ, Sutton SK, Fishman MN, Zachariah B, Heysek RV, Jacobsen PB (2016) Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Support Care Cancer 24:2201–2207
Acknowledgements
We acknowledge the excellent work of Markus Loos on the Charité prostate cancer database.
Funding
The authors received no funding for this work.
Author information
Authors and Affiliations
Contributions
Conceptualization: JB and AM; data curation: LA; writing: FF and LB; supervision: KM, AM and SH; review and editing: NS and AB.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving human participants and/or animals
The study involved human participants, but no animals.
Informed consent
We received the written informed consent from all the patients.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Friedersdorff, F., Buckendahl, L., Alt, L. et al. Analysis of quality of life and late biochemical predictors for localized cancer recurrence following radical prostatectomy. World J Urol 38, 1501–1507 (2020). https://doi.org/10.1007/s00345-019-02921-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-019-02921-5